Genmab — August 2014
-
-
citat Jan Van De Winkel: "Vi er begejstrede for at deltage i vores første samarbejde for HexaBody teknologi, som blev afsløret for godt et år siden, forskning. Denne spændende teknologi har potentiale til at øge antistof effekt i en fundamentalt ny måde. Vi er også meget glade for at indgå en anden DuoBody-platformen samarbejde og vi ser frem til at udforske det terapeutiske potentiale af produkter, der inkorporerer HexaBody og DuoBody teknologi med denne store bioteknologisk selskab udtaler Jan
-
http://www.roche.com/investors/annual_reports.htm side 135. Rituxan op 4% som top selling drug. Gazyva ikke blandt de 20 bedst sælgende - det er imponerende at rtx kører derudaf endnu !
-
https://oasm.finanstilsynet.dk/dk/vismeddelelse.aspx?aid=44387ba2-18e4-4821-b384-8889a466f0ce short position i genmab af BlueCrest
-
BCML is licensed and regulated by the Guernsey Financial Services Commission ("GFSC") under the Protection of Investors (Bailiwick of Guernsey) Law, 1987 as amended to carry on controlled investment business in or from within the Bailiwick of Guernsey
-
Husk at stil spørgsmål tl Q&A i Genmab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind